Neutral
0.0
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studie...